What happened with IVVD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Invivyd serves people with weakened immune systems who are unlikely to respond adequately to COVID-19 vaccination. Its only commercial product, PEMGARDA (pemivibart), is an antibody authorized in the United States to prevent COVID-19 before exposure in eligible adults and adolescents—not to treat an existing infection. VYD2311, its next COVID-19 antibody candidate, remains in development and is not authorized for sale.
Invivyd receives payment mainly from specialty distributors that supply PEMGARDA to healthcare providers, infusion centers and clinics. A smaller group of providers buys directly from the company. These care sites bill health insurers for the drug, so demand depends on coverage and adequate reimbursement. Most sales flow through three specialty distributors. Invivyd has no manufacturing facilities and relies on WuXi Biologics as its sole COVID-19 contract manufacturing partner.
PEMGARDA has FDA emergency-use authorization, not full approval. Continued sales depend on that authorization remaining in force and on the drug retaining activity against circulating variants: use is permitted only while variants with substantially reduced susceptibility remain within the authorization’s prevalence limit. If the relevant emergency declaration ends or the FDA revokes the authorization, Invivyd must stop selling PEMGARDA under it.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Invivyd hinges on PEMGARDA demand and protection against emerging variants, with manufacturing dependent on WuXi Biologics and antibody technology supported by Adimab.
AstraZeneca challenges Invivyd on two fronts: it develops competing COVID-19 antibodies and jointly offers Beyfortus with Sanofi for RSV prevention in infants and vulnerable young children. Its COVID-19 antibody programs matter to Invivyd’s core business, while Beyfortus serves a market that Invivyd’s still-developing VBY329 aims to enter.
Moderna and Invivyd both face changes in COVID-19 prevention demand and circulating variants, but Moderna sells vaccines while Invivyd’s PEMGARDA serves certain immunocompromised patients unlikely to respond adequately to vaccination. Moderna’s COVID-19 vaccine sales, which supplied most of its 2025 revenue, are the relevant demand signal—not a direct measure of PEMGARDA’s market.
Novavax offers a protein-based COVID-19 vaccine as an alternative to prevention with Invivyd’s PEMGARDA, but the two are not interchangeable for immunocompromised patients. PEMGARDA specifically serves certain patients unlikely to mount an adequate response to vaccination, so that distinction matters when following Novavax’s COVID-19 vaccine news.
Pfizer’s COVID-19 vaccines compete with Invivyd’s PEMGARDA as another way to prevent COVID-19, rather than as a like-for-like replacement. Pfizer sells vaccines, while PEMGARDA provides antibodies for certain immunocompromised patients unlikely to respond adequately to vaccination.
Merck’s Enflonsia already serves newborns and infants in the RSV prevention market that Invivyd’s VBY329 antibody candidate targets. Enflonsia supplies antibodies to prevent serious RSV lower respiratory tract disease in babies entering their first RSV season, making that product—not Merck’s overall medicine sales—the relevant comparison for VBY329.
Sanofi already jointly offers Beyfortus with AstraZeneca for RSV prevention in the young patients Invivyd’s VBY329 candidate aims to serve. Beyfortus is authorized for infants and children up to 24 months who remain vulnerable to severe RSV disease through their second RSV season, so its use in that group is the relevant comparison for Invivyd’s pipeline.
Merck & Co., Inc. earningsMRK
Merck's report can show whether families and care providers are using Enflonsia to prevent RSV in newborns and infants, the market Invivyd's VBY329 aims to enter.
Look for Merck's disclosures on Enflonsia sales or use. Rising uptake would show that families and care providers are using antibodies to prevent RSV in babies, while also showing that VBY329 would face an established product. Limited uptake would point to an adoption hurdle in this market, but would not establish whether VBY329 would face the same response. The takeaway is whether there is evidence of demand for RSV antibody prevention or whether adoption remains a constraint.
Invivyd, Inc. earningsThis company
Invivyd's report will show whether PEMGARDA sales growth is reducing the cash the company uses to run its business and its reliance on outside funding.
Read PEMGARDA net product revenue alongside cash used in operations and the ending cash balance. If revenue grows as operating cash use narrows, commercialization is improving the business's ability to support itself. If revenue stalls or falls while operations keep using cash, Invivyd still needs financing to support the business. Separate any financing inflow from operating cash when judging a higher ending balance; the key question is whether PEMGARDA sales are easing Invivyd's funding pressure.
Moderna, Inc. earningsMRNA
Moderna's report will show whether people and health systems are still buying COVID-19 vaccines, a broad demand signal for Invivyd's PEMGARDA but not a direct measure of its sales.
Watch the direction of Moderna's COVID-19 vaccine sales. Stable or rising sales would suggest broad demand for COVID-19 prevention remains, providing a supportive market signal for Invivyd; falling sales would point to a softer overall market. But Moderna sells vaccines, while PEMGARDA serves certain immunocompromised patients unlikely to respond adequately to vaccination, so neither outcome directly measures demand for PEMGARDA. The conclusion is about the broader demand backdrop, not Invivyd's product performance.
